Welcome to our dedicated page for Milestone Scient news (Ticker: MLSS), a resource for investors and traders seeking the latest updates and insights on Milestone Scient stock.
Milestone Scientific Inc. (MLSS) is described in its public disclosures as a technology-focused medical research and development company that patents, designs and develops computerized injection technologies and instruments for medical, dental and cosmetic applications. The company’s news flow centers on its computerized drug delivery instruments, which are designed to provide painless and precise injections using its DPS Dynamic Pressure Sensing Technology® platform.
News updates commonly cover developments in Milestone Scientific’s dental segment, including expansion of direct sales programs in North America, new international registrations for the STA® Single Tooth Anesthesia System, and initiatives such as The Wand® Ambassador Program. That program uses experienced dental professionals to share real-world clinical insights and workflow considerations to support broader adoption of The Wand STA System.
In the medical segment, news items highlight the CompuFlo® technology and the CompuFlo Epidural System, including growing utilization of CompuFlo disposables, interest from hospitals and international distributors, and progress on reimbursement strategies. Milestone Scientific reports milestones such as Medicare Part B payment-rate assignments under CPT® code 0777T in several jurisdictions and early activity from commercial insurers, which it views as important for adoption in interventional pain management and spine intervention markets.
Other recurring themes in Milestone Scientific’s news include quarterly financial results, cost-management and operational transformation efforts, leadership appointments, board changes, and updates on NYSE American listing compliance matters. Investors and observers can use this news stream to follow the company’s commercial initiatives in dental and medical markets, its reimbursement and payer-access efforts, and its corporate and governance developments over time.
Milestone Scientific (NYSE: MLSS) launched The Wand Ambassador Program to expand peer-to-peer clinical engagement and accelerate adoption of The Wand STA (Single Tooth Anesthesia) System in dentistry.
The pilot started on Dec 8, 2025 with six registered dental professionals and reported early positive feedback and inbound interest. Milestone plans to scale to approximately 250 ambassadors over 12 months, supported by onboarding, centralized learning resources, and tools that track engagement.
Management expects the program, plus expanded social media outreach, to drive ~2–3x growth in product demonstrations and improve demo-to-sales conversion efficiency while remaining capital-efficient.
Milestone Scientific (NYSE: MLSS) reported third-quarter results for the period ended September 30, 2025, highlighting cost reductions and stable revenue.
Key Q3 figures: revenue ~$2.4M (vs $2.5M), gross profit ~$1.6M (70% of revenue), operating loss $(1.1)M (improved ~23% YoY), and net loss $(1.2)M, $(0.01) per share. Nine-month revenue was ~$6.9M (+5% YoY) with a nine-month net loss of $(4.6)M, $(0.06) per share. The company said it reduced operating expenses by over $500,000 in Q3 and reported cash and cash equivalents ~$1.3M and working capital ~$3.1M. Management emphasized operational transformation, international dental growth, and increasing medical disposables recurring revenue.
Milestone Scientific (NYSE:MLSS) announced a conference call on Friday, November 14, 2025 at 8:30 AM ET to discuss third quarter results for the period ended September 30, 2025, corporate progress, and other developments.
Dial-in details: U.S. toll-free 888-506-0062, international +1 973-528-0011, access code 164353. A live webcast and replay are available at https://www.webcaster5.com/Webcast/Page/2306/53250. An audio replay is accessible through Friday, November 28, 2025 by dialing U.S. 877-481-4010 or international +1 919-882-2331 with access code 53250.
Milestone Scientific (NYSE American: MLSS) provided a business update dated October 14, 2025 outlining operational changes under new CEO Eric Hines, who joined two months earlier. Management reported a ~20% reduction in operating expenses in Q3 2025 versus Q3 2024, modest revenue growth, and an uptick in recurring revenue from CompuFlo disposables. The company plans to expand North American dental sales, strengthen direct-sales and omnichannel marketing for the STA® Single Tooth Anesthesia system, pursue new international registrations, and execute a guided relaunch and reimbursement strategy for CompuFlo in medical markets. Broad-based cost reductions and investments in market analysis aim to position the company for accelerated growth and improved financial performance.
Milestone Scientific (NYSE American: MLSS) received a notice from NYSE American dated October 8, 2025, stating it is not in compliance with Sections 1003(a)(ii) and 1003(a)(iii) of the Company Guide because stockholders' equity was approximately $3.3 million as of June 30, 2025 and the company reported losses in each of the five most recent fiscal years ended December 31, 2024.
The company must file a plan of compliance by November 7, 2025 describing steps to regain compliance by April 8, 2027. Trading of MLSS will continue on NYSE American while the company works to regain compliance; the notice does not affect day-to-day operations or SEC reporting at this time.
Milestone Scientific (NYSE:MLSS), developer of computerized drug delivery instruments, has appointed Dr. Dawood Sayed to its Board of Directors. Dr. Sayed, a Professor of Anesthesiology and Pain Medicine at the University of Kansas Medical Center, brings extensive expertise in interventional pain medicine and neuromodulation.
The appointment strengthens the company's clinical and commercial strategy for its CompuFlo® Epidural System, which recently received Medicare Part B payment coverage under CPT® code 0777T. Dr. Sayed's experience with health system adoption, clinical training, and reimbursement strategy is expected to accelerate MLSS's growth in the interventional pain management market.
Milestone Scientific (NYSE:MLSS), a developer of computerized drug delivery instruments, reported strong Q2 2025 financial results with a 25% revenue increase to $2.3 million. The growth was primarily driven by international dental sales, which more than doubled year-over-year, maintaining a robust 70% gross margin.
The company has strengthened its leadership team with the appointment of Eric Hines as CEO, Jason Papes as SVP of Global Sales and Marketing, and Shanth Thiyagalingam joining the Board of Directors. Despite revenue growth, the company reported an operating loss of $(1.5) million and ended Q2 with $1.3 million in cash and $3.9 million in working capital.
Notable progress includes securing Medicare Part B payment coverage, gaining commercial insurer support for the CompuFlo® Epidural System, and expanding through the Federal Supply Schedule contract.
Milestone Scientific (NYSE:MLSS), a developer of computerized drug delivery instruments for painless and precise injections, has scheduled its Q2 2025 financial results conference call for Friday, August 15th, 2025, at 8:00 AM ET.
The call will discuss Q2 2025 financial performance, corporate progress, and other developments. Investors can access the call via phone (U.S. toll-free: 888-506-0062; International: +1 973-528-0011; Access code: 470429) or webcast. A replay will be available through August 29th, 2025.
Milestone Scientific (NYSE:MLSS), a developer of computerized drug delivery instruments, has appointed Jason Papes as Senior Vice President, Global Head of Sales and Marketing. Papes brings over 30 years of healthcare industry experience, notably as Founder of TEN20 Medical Distribution and executive positions at Stryker Imaging and Brainlab.
The appointment comes at a crucial time as MLSS advances the commercial rollout of its CompuFlo® Epidural System, which recently received Medicare Part B payment rates under CPT® code 0777T. The company is also expanding its dental segment through the STA Single Tooth Anesthesia® System. Papes will be instrumental in scaling both platforms and implementing market access strategies.
Milestone Scientific (NYSE:MLSS), a developer of computerized drug delivery instruments, has appointed Eric C. Hines as its new Chief Executive Officer. Hines brings over 25 years of leadership experience in scaling sales-driven enterprise software companies, most recently serving as President of North America at Ex Libris where he doubled annual revenue from $50M to $100M.
The appointment comes at a crucial time as Milestone Scientific advances its CompuFlo® technology, having secured Medicare Part B payment rates under CPT® code 0777T and initial commercial insurance payments. Hines' experience in healthcare and track record of commercial expansion positions him to drive adoption of the company's technology in medical and dental markets while pursuing new clinical indications and global opportunities.
FAQ
What is the current stock price of Milestone Scient (MLSS)?
What is the market cap of Milestone Scient (MLSS)?
